Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study).
Driessen CM, Ham JC, Te Loo M, van Meerten E, van Lamoen M, Hakobjan MH, Takes RP, van der Graaf WT, Kaanders JH, Coenen MJH, van Herpen CM. Driessen CM, et al. Among authors: ham jc. Cancers (Basel). 2019 Apr 17;11(4):551. doi: 10.3390/cancers11040551. Cancers (Basel). 2019. PMID: 30999660 Free PMC article.
Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study.
Ham JC, Driessen CM, Hendriks MP, Fiets E, Kreike B, Hoeben A, Slingerland M, van Opstal CC, Kullberg BJ, Jonker MA, Adang EM, Kaanders JH, van der Graaf WT, van Herpen CM. Ham JC, et al. Eur J Cancer. 2019 May;113:32-40. doi: 10.1016/j.ejca.2019.02.013. Epub 2019 Apr 6. Eur J Cancer. 2019. PMID: 30965213 Clinical Trial.
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
Ham JC, van Meerten E, Fiets WE, Beerepoot LV, Jeurissen FJF, Slingerland M, Jonker MA, Husson O, van der Graaf WTA, van Herpen CML. Ham JC, et al. Head Neck. 2020 May;42(5):828-838. doi: 10.1002/hed.26053. Epub 2020 Jan 6. Head Neck. 2020. PMID: 31903657 Free PMC article. Clinical Trial.
Acute erythema of the face after methotrexate.
Ham JC, Verhoef CG, van Herpen CM. Ham JC, et al. Neth J Med. 2016 Jan;74(1):49-50. Neth J Med. 2016. PMID: 26819365 Free article. No abstract available.
Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.
Caetano-Pinto P, Jamalpoor A, Ham J, Goumenou A, Mommersteeg M, Pijnenburg D, Ruijtenbeek R, Sanchez-Romero N, van Zelst B, Heil SG, Jansen J, Wilmer MJ, van Herpen CML, Masereeuw R. Caetano-Pinto P, et al. Mol Pharm. 2017 Jun 5;14(6):2147-2157. doi: 10.1021/acs.molpharmaceut.7b00308. Epub 2017 May 24. Mol Pharm. 2017. PMID: 28493713 Free PMC article.
[A man with neutropenic fever].
Ham JC, Ruijs GJ, van Marwijk Kooy MR. Ham JC, et al. Ned Tijdschr Geneeskd. 2013;157(12):A5997. Ned Tijdschr Geneeskd. 2013. PMID: 23515043 Dutch.
21 results